Table 2.
Expression of the NKG2D and DNAM-1 ligands on RMS tumor cells in biopsy sections
| Patient # | NKG2D ligands | DNAM-1 ligands | ||
|---|---|---|---|---|
| MICA | ULBP1 | CD112 | CD155 | |
| 1 | ++ | + | − | + |
| 2 | + | − | + | − |
| 3 | + | + | + | − |
| 4 | + | − | − | − |
| 5 | + | − | − | ++ |
| 6 | ++ | − | + | − |
| 7 | − | + | − | + |
| 8 | + | − | + | − |
Expression of ligands for the activating NK cell receptors (NKG2D, DNAM-1) was determined on RMS biopsy sections of 8 ERMS patients by immunohistochemistry (−: no staining or weak membrane staining in <10 % of the tumor cells; +: range of weak staining in at least 10 % of the tumor cells to intense membrane staining in ≤30 % of the tumor cells; ++: intense membrane staining in >30 % of the tumor cells)